Effect of Smad pathway activation on podocyte cell cycle regulation: An immunohistochemical evaluation

Renal Failure

Volumn 36, Issue 8, 2014, Pages 1310-1316

  Koutroutsos, Konstantinos ^a   Kassimatis, Theodoros I ^a,b   Nomikos, Alexandros ^a,b   Giannopoulou, Ioanna ^a   Theohari, Irene ^a   Nakopoulou, Lydia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Asklepieion General Hospital   (Greece)

Author keywords

Glomerulonephritis; Immunohistochemistry; P57; Podocytes; Smad

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1C; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEIN;

ADULT; ARTICLE; CELL CYCLE REGULATION; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IMMUNE COMPLEX NEPHRITIS; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; PODOCYTE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEINURIA; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL CYCLE; CYTOLOGY; GLOMERULONEPHRITIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADULT; CELL CYCLE; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PODOCYTES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84906687076     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.937664     Document Type: Article

References (67)

1. Vidal A, Koff A. Cell-cycle inhibitors: Three families united by a common cause. Gene. 2000;247:1-15.
2. Yan Y, Frisen J, Lee MH, Massague J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997;11: 973-983.
3. Wang S, Kim JH, Moon KC, Hong HK, Lee HS. Cell cycle mechanisms involved in podocyte proliferation in cellular lesion of focal segmental glomerulosclerosis. Am J Kidney Dis. 2004;43: 19-27.
4. Bariety J, Bruneval P, Meyrier A, Mandet C, Hill G, Jacquot C. Podocyte involvement in human immune crescentic glomerulo-nephritis. Kidney Int. 2005;68:1109-1119.
5. Ding M, Cui S, Li C, Jothy S, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med. 2006;12:1081-1087.
6. Thorner PS, Ho M, Eremina V, Sado Y, Quaggin S. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol. 2008;19:495-502.
7. Smeets B, Uhlig S, Fuss A, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol. 2009;20:2604-2615.
8. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol. 2002;13:2600-2610.
9. Schnaper HW, Hayashida T, Poncelet AC. It's a Smad world: Regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol. 2002;13:1126-1128.
10. Liu Y. Renal fibrosis: New insights into the pathogenesis and therapeutics. Kidney Int. 2006;69:213-217.
11. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS. Activation of the TGF-b/Smad signaling pathway in focal segmental glomerulo-sclerosis. Kidney Int. 2003;64:1715-1721.
12. Kim TS, Kim JY, Hong HK, Lee HS. mRNA expression of glomerular basement membrane proteins and TGF-b1 in human membranous nephropathy. J Pathol. 1999;189:425-430.
13. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-b1 develop progressive renal disease. Lab Invest. 1996;74:991-1003.
14. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor b1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 1995;92:2572-2576.
15. Shimizu M, Kondo S, Urushihara M, et al. Role of integrin-linked kinase in epithelial mesenchymal transition in crescent formation of experimental glomerulonephritis. Nephrol Dial Transplant. 2006; 21:2380-2390.
16. Kim HW, Moon KC, Park SY, Hong HK, Lee HS. Differential expression of platelet-derived growth factor and transforming growth factor-b in relation to progression of IgA nephropathy. Nephrology. 2002;7:S131-S139.
17. Patek CE, Fleming S, Miles CG, et al. Murine Denys-Drash syndrome: Evidence of podocyte dedifferentiation and systemic mediation of glomerulosclerosis. Hum Mol Genet. 2003;12: 2379-2394.
18. Lee HS, Song CY. Effects of TGF-b on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res. 2010;33:24-29.
19. Franzen P, Ten Dijke P, Ichijo H, et al. Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell. 1993;75:681-692.
20. Massague J, Blain SW, Lo RS. TGF-b signalling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
21. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-bJreceptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16:5353-5362.
22. Zawel L, Dai JL, Buckhaults P, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998;1: 611-617.
23. Massague J, Wotton D. Transcriptional control by TGF-bJ/Smad signaling. EMBO J. 2000;19:1745-1754.
24. Nakao A, Afrakhte M, Moren A, et al. Identification of Smad7, aTGFbeta-inducible antagonist of TGF-beta signalling. Nature. 1997;389:631-635.
25. Shi Y, Massague J. Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell. 2003;113:685-700.
26. de Caestecker MP, Yahata T, Wang D, et al. The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem. 2000;275:2115-2122.
27. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF. TGF-beta-induced phosphorylation of Smad3 regulates its interaction with co-activator p300/CREBbinding protein. Mol Biol Cell. 1998;9:3309-3319.
28. Hong SW, Isono M, Chen S, et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol. 2001;158:1653-1663.
29. Kanamaru Y, Nakao A, Tanaka Y, et al. Involvement of p300 in TGF-beta/Smad-pathway mediated alpha2(I) collagen expression in mouse mesangial cells. Nephron Exp Nephrol. 2003;95:e36-e42.
30. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. 2002;13: 1464-1472.
31. Yamashita S. Ontogenic expression of estrogen receptor co-activators in the reproductive tract of female mice neonatally exposed to diethylstilbestrol. Reprod Toxicol. 2004;18:275-284.
32. Bussolati G, Gugliotta P, Volante M, Pace M, Papotti M. Retrieved endogenous biotin: A novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology. 1997;31: 400-407.
33. Vyberg M, Nielsen S. Dextran polymer conjugate two step visualization system for immunohistochemistry. A comparison of EnVision+ with two three step avidinbiotin techniques. Appl Immunohistochem. 1998;61:3-10.
34. Sabattini E, Bisgaard K, Ascani S, et al. The EnVisionTM+ system: A new immunohistochemical method for diagnostics and research. Critical comparison with APAAP, ChemMateTM, CSA, LABC, and SABC techniques. J Clin Pathol. 1998;51:506-511.
35. Kassimatis TI, Giannopoulou I, Koumoundourou D, Theodorakopoulou E, Varakis I, Nakopoulou L. Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: Correlation with renal injury. J Cell Mol Med. 2006;10(4):908-921.
36. Flanders K, Kim E, Roberts A. Immunohistochemical expression of Smads 1-6 in the 15-day gestation mouse embryo: Signaling by BMPs and TGF-betas. Dev Dyn. 2001;220:141-154.
37. Vrljicak P, Myburgh D, Ryan AK. Smad expression during kidney development. Am J Physiol Renal Physiol. 2004;286:F625-F633.
38. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation and development. Genes Dev. 2000;14:1553-1577.
39. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: Role in podocyte proliferation and maturation. Kidney Int. 2000;58(2):674-683.
40. Srivastava T, Garola RE, Singh HK. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children. Kidney Int. 2006;70(3):529-533.
41. Hiromura K, Haseley LA, Zhang P, et al. Podocyte expression of the CDK inhibitor p57 during development and disease. Kidney Int. 2001;60(6):2235-2246.
42. Nishimori S, Tanaka Y, Chiba T, et al. Smad-mediated transcription is regulated for transforming growth factor-beta 1-induced p57(kip2) proteolysis in osteoblastic cells. J Biol Chem. 2001; 276:10700-10705.
43. Urano T, Yashiroda H, Muraoka M, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. J Biol Chem. 1999;274: 12197-12200.
44. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteo-blast cell differentiation. EMBO Rep. 2008;9:878-884.
45. Scandura JM, Boccuni P, Massaque J, et al. Transforming growth factor b-induced cell cycle arrest of hematopoietic cells requires p57kip2 up-regulation. Proc Natl Acad Sci. 2004;101: 15231-15236.
46. Chen Z, Li DQ, Tong L, et al. Targeted inhibition of p57 and p15 blocks transforming growth factor beta-inhibited proliferation of primary cultured human limbal epithelial cells. Mol Vis. 2006;23: 983-994.
47. Sinuani I, Weissgarten J, Beberashvili I, et al. The cyclin kinase inhibitor p57kip2 regulates TGF-beta-induced compensatory tubular hypertrophy: Effect of the immunomodulator AS101. Nephrol Dial Transplant. 2009;24(8):2328-2338.
48. Liu B, Preisig PA. TGF-b-mediated hypertrophy in rat renal epithelial cells involves inhibiting phosphorylation by preventing activation of cdk2/cyclin E kinase. Am J Physiol. 1999;277: 186-194.
49. Bowers EM, Yan G, Mukherjee C, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem Biol. 2010;17:471-482.
50. Iyer NG, Xian J, Chin SF, et al. p300 is required for orderly G1/S transition in human cancer cells. Oncogene. 2007;26:21-29.
51. Heemers HV, Debes JD, Tindall DJ. The role of the transcriptional coactivator p300 in prostate cancer progression. Adv Exp Med Biol. 2008;617:535-540.
52. Wang W, Koka V, Lan HY. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton). 2005;10: 48-56.
53. Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab. 1998;24:111-119.
54. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1-and Th17-cell differentiation. Immunity. 2007;26:579-591.
55. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and-independent mechanisms. Immunity. 2006;25:455-471.
56. Chernajovsky Y, Adams G, Triantaphyllopoulos K, Ledda MF, Podhajcer OL. Pathogenic lymphoid cells engineered to express TGF beta 1 ameliorate disease in a collagen-induced arthritis model. Gene Ther. 1997;4:553-1539.
57. Subra JF, Cautain B, Xystrakis E, et al. The balance between CD45RChigh and CD45RClow CD4 T cells in rats is intrinsic to bone marrow-derived cells and is genetically controlled. J Immunol. 2001;166:2944-2952.
58. Fuss IJ, Boirivant M, Lacy B, Strober W. The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis. J Immunol. 2002;168:900-908.
59. Hansen G, McIntire JJ, Yeung VP, et al. CD4 T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 2000;105: 61-70.
60. Afrakhte M, Moren A, Jossan S, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. Biochem Biophys Res Commun. 1998;249:505-511.
61. Zhu HJ, Iaria J, Sizeland AM. Smad7 differentially regulates transforming growth factor betamediated signaling pathways. J Biol Chem. 1999;274:32258-32264.
62. Lan HY, Mu W, Tomita N, et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol. 2003;14:1535-1548.
63. Hou CC, Wang W, Huang XR, et al. Ultrasound-microbubbleme-diated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol. 2005;166:761-771.
64. Uchida K, Nitta K, Kobayashi H, et al. Localization of Smad6 and Smad7 in the rat kidney and their regulated expression in the anti-Thy-1 nephritis. Mol Cell Biol Res Commun. 2000;4:98-105.
65. Fukasawa H, Yamamoto T, Togawa A, et al. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci USA. 2004;101:8687-8692.
66. Chen H, Huang XR, Wang W, et al. The protective role of Smad7 in diabetic kidney disease: Mechanism and therapeutic potential. Diabetes. 2010;60:590-601.
67. Wang W, Huang XR, Li AG, et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: Role of Smad7. J Am Soc Nephrol. 2005;16:1371-1383.